Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.62 |
| ▸ | HTR4 | Q13639 | 12/20 | 0.57 |
| ▸ | HTR3A | P46098 | 1/20 | 0.57 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6306539 | 0.94 | KCNH2 (0.61) | KCNH2HTR4HTR3ACACNA1IDRD2 | |
| SCHEMBL5889424 | 0.92 | KCNH2 (0.59) | KCNH2HTR4HTR3ADRD2DRD4 | |
| SCHEMBL5889439 | 0.91 | KCNH2 (0.61) | KCNH2HTR4HTR3ACACNA1I | |
| SCHEMBL6246866 | 0.90 | KCNH2 (0.61) | KCNH2HTR4HTR3ACACNA1IDRD2 | |
| SCHEMBL5889579 | 0.89 | KCNH2 (0.77) | KCNH2HTR4HTR3ACACNA1IDRD2 | |
| SCHEMBL6703751 | 0.89 | KCNH2 (0.60) | KCNH2HTR4HTR3ACACNA1I | |
| SCHEMBL6767167 | 0.88 | KCNH2 (0.62) | KCNH2HTR4HTR3A | |
| SCHEMBL6314932 | 0.88 | KCNH2 (0.58) | KCNH2HTR4HTR3ACACNA1IDRD2 | |
| SCHEMBL7240727 | 0.86 | KCNH2 (0.60) | KCNH2HTR4HTR3ADRD2DRD4 | |
| SCHEMBL8345408 | 0.86 | KCNH2 (0.68) | KCNH2HTR4HTR3ADRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7012080-B2 | Imidazopyridine compounds as 5-HT4 receptor agonists | PFIZER INC. (US) | 2006-03-14 | — | — | US | disclosed |
| US-20040122043-A1 | Imidazopyridine compounds as 5-HT4 receptor agonists | PFIZER INC | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122043-A1 | Imidazopyridine compounds as 5-HT4 receptor agonists | HTR4, GPR4, HRH4 | KCNH2 840/4885HTR4 1/4885HTR3A 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.